Floatz logo

LENVATINIB

Pathological Complete Response

Seoul National University HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pathological Complete Response cohort.

Asset / SponsorPhaseRating
Capecitabine
The First Affiliated Hospital of Anhui Medical University
Phase 2CCC
Eloxatin
The First Affiliated Hospital of Anhui Medical University
Phase 2CCC
Tislelizumab
Seoul National University Hospital
D

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →